Table 2.
Treatments received on study for KSHV-MCD alone or with concurrent KS, median duration of treatment, and 5-year PFS
| Treatment | Number of patients receiving protocol treatment | Median duration of treatment leading to KSHV-MCD remission, mo | 5-y PFS, % (95% CI) | P† | |||
|---|---|---|---|---|---|---|---|
| All patients treated | MCD alone | MCD with concurrent KS | As first regimen on protocol (%)* | ||||
| AZT/VGC | 17 | 6 | 11 | 17 (100) | 5 | 26 (8, 49) | — |
| Rituximab alone | 8 | 6 | 2 | 5 (63) | 1 | 71 (26, 92) | .03 |
| Rituximab and liposomal doxorubicin | 36 | 7 | 29 | 22 (61) | 5 | 73 (53, 86) | — |
| No maintenance | 16 | 1 | 15 | 13 (81) | 2 | 62 (23, 85) | .02 |
| AZT/VGC maintenance | 10 | 5 | 5 | 7 (70) | 11 (9 mo of AZT/VGC in maintenance phase) | 87 (39, 98) | .0009 |
| IFN-α maintenance | 10 | 1 | 9 | 2 (20) | 7 (4 mo of IFN-α in maintenance phase) | 70 (33, 89) | .01 |
*
Values shown are the number of patients treated as the first regimen on protocol; “%” indicates first regimen on the protocol among all patients treated with that regimen.
†
P values are log-rank tests of PFS comparing AZT/VGC with other KSHV-MCD regimens used that are adjusted for multiple comparisons (Bonferroni test). Patients who received (DA)EPOCH±R (8 patients) are not included in this table.